捷隆控股(01425.HK)2021年純利增長50%至1.58億港元 末期息0.059港元
格隆匯3月30日丨捷隆控股(01425.HK)發佈公吿,截至2021年12月31日止年度,公司收益11.8億港元,同比增長37.8%;公司擁有人應占溢利1.58億港元,同比增長50%;每股盈利12.67港仙,董事會建議宣派及派付末期股息每股港幣0.059元。
於2021年,集團的睡衣及家居便服產品銷售量約為28,300,000件,與2020年的銷售量比較,增加了約32.7%。此外,於2021年公司的其他業務例如銷售坯布及提供加工服務亦有輕微的上升。而由於產品組合的改變,睡衣及家居便服產品的平均售價較2020年輕微上升約2.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.